AMGEN INC.
🏢 View company profile →1,951Patents
1,352Active
1,951Granted
61Portfolio score
Filing activity: May 6, 1982 → Jun 26, 2025 · 401 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5625050A | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics | Chemistry; Metallurgy | 517 | Expired |
| US5824784A | N-terminally chemically modified protein compositions and methods | Human Necessities | 367 | Expired |
| US6660843B1 | Modified peptides as therapeutic agents | Chemistry; Metallurgy | 349 | Expired |
| US8592562B2 | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects | Chemistry; Metallurgy | 268 | Active |
| US5284656A | Pulmonary administration of granulocyte colony stimulating factor | Emerging Cross-Sectional Technologies | 237 | Expired |
| US6096728A | Composition and method for treating inflammatory diseases | Human Necessities | 209 | Expired |
| US4762779A | Compositions and methods for functionalizing nucleic acids | Chemistry; Metallurgy | 207 | Expired |
| US4739044A | Method for derivitization of polynucleotides | Chemistry; Metallurgy | 196 | Expired |
| US5399361A | Collagen-containing sponges as drug delivery compositions for proteins | Emerging Cross-Sectional Technologies | 186 | Expired |
| US4695623A | Consensus human leukocyte interferon | Emerging Cross-Sectional Technologies | 184 | Expired |
| US4999291A | Production of human pluripotent granulocyte colony-stimulating factor | Human Necessities | 183 | Expired |
| US5783186A | Antibody-induced apoptosis | Chemistry; Metallurgy | 182 | Expired |
| US6586398B1 | Chemically modified novel erythropoietin stimulating protein compositions and methods | Human Necessities | 170 | Expired |
| US6420339B1 | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility | Human Necessities | 160 | Expired |
| US4751177A | Methods and kits for performing nucleic acid hybridization assays | Emerging Cross-Sectional Technologies | 160 | Expired |
| US4897471A | Consensus human leukocyte interferon | Emerging Cross-Sectional Technologies | 154 | Expired |
| US6939874B2 | Substituted pyrimidinyl derivatives and methods of use | Chemistry; Metallurgy | 152 | Expired |
| US5580755A | Human pluripotent granulocyte colony-stimulating factor | Human Necessities | 151 | Expired |
| US4652639A | Manufacture and expression of structural genes | Physics | 151 | Expired |
| US6451346B1 | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents | Human Necessities | 133 | Expired |
| US5512301A | Collagen-containing sponges as drug delivery compositions for proteins | Emerging Cross-Sectional Technologies | 132 | Expired |
| US5756349A | Production of erythropoietin | Chemistry; Metallurgy | 132 | Expired |
| US8030457B2 | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) | Chemistry; Metallurgy | 124 | Active |
| US5372808A | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect | Emerging Cross-Sectional Technologies | 118 | Expired |
| US5476653A | Polyoxymethylene-oxyethylene copolymers in conjuction with biomolecules | Emerging Cross-Sectional Technologies | 115 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.